3C
AMED

361 Capital’s Amedisys AMED Stock Holding History

361 Capital’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-3,745
Closed -$687K – 303
2020
Q1 		$687K Sell
3,745
-6,107
-62% -$1.09M 0.31% 161
2019
Q4 		$1.64M Sell
9,852
-10,939
-53% -$1.63M 0.46% 40
2019
Q3 		$2.72M Sell
20,791
-472
-2% -$61.4K 0.5% 49
2019
Q2 		$2.58M Sell
21,263
-1,504
-7% -$178K 0.46% 108
2019
Q1 		$2.81M Buy
22,767
+1,957
+9% +$246K 0.49% 77
2018
Q4 		$2.44M Buy
20,810
+5,245
+34% +$618K 0.5% 53
2018
Q3 		$1.95M Sell
15,565
-4,754
-23% -$525K 0.42% 65
2018
Q2 		$1.74M Buy
+20,319
New +$1.49M 0.39% 86

Other funds holding AMED

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

361 Capital's AMED Position: Q2 2020 in Review

361 Capital sold out of Amedisys (AMED) in Q2 2020, closing a stake of 3,745 shares — an estimated $687K sold.

361 Capital first reported a position in AMED in Q2 2018 and held it in 8 quarters. The position peaked at $2.81M in Q1 2019. 355 funds tracked by Wall St. Rank hold AMED as of Q2 2020.

  • 361 Capital reported no remaining Amedisys position as of Q2 2020 after selling out during the quarter.
  • 361 Capital sold 3,745 Amedisys shares in Q2 2020, an estimated $687K.
  • 361 Capital first reported a position in Amedisys in Q2 2018 and held it in 8 quarters.
  • 361 Capital's Amedisys position peaked at $2.81M in Q1 2019.
  • 355 funds tracked by Wall St. Rank held Amedisys as of Q2 2020.

Based on 361 Capital's 13F filing for Q2 2020, filed 14 Aug 2020.